Drugs / FSME IMMUN NEW
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00161772 | Mar → Aug 2002 | tick-borne encephalitis | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00161798 | Sep 2001 → Mar 2002 | tick-borne encephalitis | Pfizer | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00161863 | Sep 2002 → Jan 2003 | tick-borne encephalitis | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00161824 | Oct 2001 → Jan 2002 | tick-borne encephalitis | Pfizer | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FSME IMMUN NEW | “The purpose of this study is to assess the safety of a vaccination schedule consisting of two vaccinations (21-35 days apart) with the tick-borne encephalitis (TBE) vaccine...” NCT00161824 ↗3“Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.” NCT00161798 ↗ “Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.” NCT00161772 ↗ |
| Modality | Vaccine | “a TBE vaccine” NCT00161772 ↗ |